Skip to content

Effects of Rivastigmine on reactivity based on the cholinesterase polymorphism in Alzheimer's patients

Effects of Rivastigmine on reactivity based on the cholinesterase polymorphism in Alzheimer's patients - ERVIS trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000052878
Enrollment
200
Registered
2023-11-24
Start date
2020-09-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dementia

Interventions

The intervention group underwent 90 min of group-based weekly physical exercise, cognitive training, nutritional counseling, and vascular risk factor management for 18 months (78 sessions in total). I

Sponsors

Kobe University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria were as follows: Tamba City resident, age 65-85 at enrollment, dementia assessment sheet 21 items in the community comprehensive care system (DASC-21) 10 score between 22 and 30, and at least one of the following as vascular risk: treated hypertension, systolic blood pressure over 140 mmHg or diastolic blood pressure over 85 mmHg, or treated diabetes (HbA1c over 6.0%) as vascular risk.

Exclusion criteria

Exclusion criteria: Those with a Mini-Mental State Examination (MMSE)11 score <24 and those already receiving public long-term care were excluded from the study.

Design outcomes

Primary

MeasureTime frame
The amount of change in cognitive function (composite score) from the time of enrollment to 18 months later. The composite score is calculated from the Z-scores of the MMSE, FCSRT, logical memory, DSST, TMT, counting, and word recall tasks.

Countries

Japan

Contacts

Public ContactYutaro Oki

Kobe University Graduate School of Health Sciences

oki@carp.kobe-u.ac.jp078-796-4502

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026